| Identification | Back Directory | [Name]
CT-1812 | [CAS]
1802632-22-9 | [Synonyms]
Elayta
CT-1812
Sigma-2 receptor antagonist 1
ELAYTA;CT 1812;CT-1812;CT1812
2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol
4-[3-[1,3-Dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)phenol
Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)- | [Molecular Formula]
C24H33NO4S | [MDL Number]
MFCD31813891 | [MOL File]
1802632-22-9.mol | [Molecular Weight]
431.59 |
| Chemical Properties | Back Directory | [Boiling point ]
588.0±50.0 °C(Predicted) | [density ]
1.176±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 250 mg/mL (579.25 mM; Need ultrasonic) | [form ]
Solid | [pka]
9.88±0.45(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CT1812 (Sigma-2 receptor antagonist 1) is an orally active and brain penetrant sigma-2 receptor antagonist with a Ki of 8.5 nM. CT1812 can be used for the research of Alzheimer’s disease[1]. | [in vivo]
CT1812 (0.3-3 mg/kg, i.v., once time) selectively reduces Aβ oligomer extracellular concentrations in transgenic hAPP/PS1 mice[1].
CT1812 (10 mg/kg, p.o., daily, 9-10 weeks) improves cognitive performance in transgenic Thy1 huAPPSwe/Lnd+ male mice[1].
| [IC 50]
Sigma 2 Receptor | [References]
[1] Izzo NJ, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021 Aug;17(8):1365-1382. DOI:10.1002/alz.12302 |
|
|